Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,506.48
(
-1.51%
)
US TECH 100
23,012.00
(
-1.16%
)
Dow Jones
45,577.47
(
-0.96%
)
Brent Oil
109.79
(
1.54%
)
Bitcoin
68,207.29
(
0.54%
)
News Focus
News Focus
Post# of 257269
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122806
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: willyw post# 182121

Tuesday, 09/23/2014 11:20:27 AM

Tuesday, September 23, 2014 11:20:27 AM

Post# of 257269

what if Gilead had experimented with RBV or dosing strengths or treatment durations in genotype 2 or 3? Oh wait; they have and they are currently doing so, and they probably will continue to do so in optimizing efficacy/safety/duration in drug treatments.

True for GT3, which is turning out to be the hardest genotype to treat for many all-oral regimens. On the other hand, GILD seems to have GT2 well covered already.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today